Detection of MET alterations at the DNA, RNA and protein levels in NSCLC patients progressing on ALK and ROS1 targeted therapies

被引：0
|
作者：
Jordana-Ariza, Nuria [1 ]
Reischmann, Nadine [2 ]
Esparre, Carlos [1 ]
Roman, Ruth [1 ]
Aguado-Esteban, Cristina [1 ]
Garcia-Roman, Silvia [1 ]
Stroh, Christopher [2 ]
Aguilar, Andres Aguilar [1 ]
Rosell, Rafael [1 ]
Karachaliou, Niki [2 ]
Molina-Vila, Miguel A. [1 ]
机构：
[1] Hosp Univ Dexeus, Barcelona, Spain
[2] Merck Healthcare KGaA, Darmstadt, Germany
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1106
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
    Jordana, N.
    Esparre, C.
    Roman, R.
    Aguado, C.
    Garcia, B.
    Vives, M.
    Marin, E.
    Garcia-Roman, S.
    Aguilar, A.
    Reguart, N.
    Rosell, R.
    Molina-Vila, M. A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S459 - S459
  • [2] Different ALK/ROS1 Variants in Prognosis of Surgical NSCLC Patients
    Zhao, Chao
    Li, Xuefei
    Su, Chuanxia
    Ren, Shengxiang
    Chen, Xiaoxia
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1508 - S1509
  • [3] Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
    Stucklin, Ana S. Guerreiro
    Boue, Daniel R.
    Finlay, Jonathan L.
    Coven, Scott L.
    de Prada, Inmaculada
    Perez-Somarriba, Marta
    Faria, Claudia C.
    Grotzer, Michael A.
    Rushing, Elisabeth
    Sumerauer, David
    Zamecnik, Josef
    Krskova, Lenka
    Garcia Ariza, Miguel
    Cruz, Ofelia
    Morales La Madrid, Andres
    Solano, Palma
    Terashima, Keita
    Nakano, Yoshiko
    Ichimura, Koichi
    Nagane, Motoo
    Sakamoto, Hiroaki
    Joao Gil-da-Costa, Maria
    Silva, Roberto
    Johnston, Donna L.
    Michaud, Jean
    Wilson, Bev
    van Landeghem, Frank K. H.
    Oviedo, Angelica
    McNeely, P. Daniel
    Crooks, Bruce
    Fried, Iris
    Zhukova, Nataliya
    Hansford, Jordan R.
    Nageswararao, Amulya
    Garzia, Livia
    Shago, Mary
    Brudno, Michael
    Irwin, Meredith S.
    Bartels, Ute
    Ramaswamy, Vijay
    Bouffet, Eric
    Taylor, Michael D.
    Tabori, Uri
    Hawkins, Cynthia
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [4] Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
    Ana S. Guerreiro Stucklin
    Scott Ryall
    Kohei Fukuoka
    Michal Zapotocky
    Alvaro Lassaletta
    Christopher Li
    Taylor Bridge
    Byungjin Kim
    Anthony Arnoldo
    Paul E. Kowalski
    Yvonne Zhong
    Monique Johnson
    Claire Li
    Arun K. Ramani
    Robert Siddaway
    Liana Figueiredo Nobre
    Pasqualino de Antonellis
    Christopher Dunham
    Sylvia Cheng
    Daniel R. Boué
    Jonathan L. Finlay
    Scott L. Coven
    Inmaculada de Prada
    Marta Perez-Somarriba
    Claudia C. Faria
    Michael A. Grotzer
    Elisabeth Rushing
    David Sumerauer
    Josef Zamecnik
    Lenka Krskova
    Miguel Garcia Ariza
    Ofelia Cruz
    Andres Morales La Madrid
    Palma Solano
    Keita Terashima
    Yoshiko Nakano
    Koichi Ichimura
    Motoo Nagane
    Hiroaki Sakamoto
    Maria Joao Gil-da-Costa
    Roberto Silva
    Donna L. Johnston
    Jean Michaud
    Bev Wilson
    Frank K. H. van Landeghem
    Angelica Oviedo
    P. Daniel McNeely
    Bruce Crooks
    Iris Fried
    Nataliya Zhukova
    Nature Communications, 10
  • [5] Novel targeted therapy beyond EGFR and ALK: ROS1, BRAF, RET and MET
    Yoh, Kiyotaka
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC
    Linea Melchior
    Astrid Hirschmann
    Paul Hofman
    Christophe Bontoux
    Angel Concha
    Salima Mrabet-Dahbi
    Pascal Vannuffel
    Emmanuel Watkin
    Martina Putzová
    Stefania Scarpino
    Anne Cayre
    Paloma Martin
    Robert Stoehr
    Arndt Hartmann
    Virchows Archiv, 2024, 484 : 677 - 686
  • [7] Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC
    Melchior, Linea
    Hirschmann, Astrid
    Hofman, Paul
    Bontoux, Christophe
    Concha, Angel
    Mrabet-Dahbi, Salima
    Vannuffel, Pascal
    Watkin, Emmanuel
    Putzova, Martina
    Scarpino, Stefania
    Cayre, Anne
    Martin, Paloma
    Stoehr, Robert
    Hartmann, Arndt
    VIRCHOWS ARCHIV, 2024, 484 (04) : 677 - 686
  • [8] Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling
    Le, Xiuning
    Freed, Jason A.
    VanderLaan, Paul A.
    Huberman, Mark S.
    Rangachari, Deepa
    Jorge, Susan E.
    Lucena-Araujo, Antonio R.
    Kobayashi, Susumu S.
    Balasubramanian, Sohail
    He, Jie
    Chudnovsky, Yakov
    Miller, Vincent A.
    Ali, Siraj M.
    Costa, Daniel B.
    CLINICAL LUNG CANCER, 2015, 16 (05) : E105 - E109
  • [9] Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma
    Tang, Zhenya
    Zhang, Jianjun
    Lu, Xinyan
    Wang, Wei
    Chen, Hui
    Robinson, Melissa K.
    Cheng, Joanne
    Tang, Guilin
    Medeiros, L. Jeffrey
    MODERN PATHOLOGY, 2018, 31 (02) : 307 - 312
  • [10] Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients with NSCLC Highlights Correlation of ROS1 and PD-L1 Expression
    Kim, T.
    Lee, J.
    Na, J. I.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S555 - S555
12345